Key clinical point: A significant portion of public speakers at certain FDA advisory committee meetings have conflicts of interest.
Major finding: Of 112 speakers, about 25% had a conflict of interest, of which about 20% were undisclosed.
Study details: A study of public speakers at 15 Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) meetings from September 2009 through April 2017 related to the approval of drug products.
Disclosures: Dr. McCoy reports that his spouse is employed by a cancer patient advocacy organization. Dr. Litman reports that he is a member of AADPAC. No other disclosures were reported.
Read the full story here.